Merck Millipore Launches Single-Use Process Container Film for High-Volume Biopharmaceutical Applications
Merck Millipore has expanded its single-use film offerings with the introduction of PureFlex Plus film, a robust, durable film used in the construction of Mobius single-use process containers for biopharmaceutical manufacturing. The film's rugged outer layer offers strong resistance to leak formation, making it ideal for the demanding applications often encountered in large volume operations.
PureFlex Plus film adds a new, more robust linear low density polyethlene (LLDPE) outer layer, which reduces susceptibility to leaks through abrasion, puncture, stretching and tearing. The inner layers of PureFlex Plus film are identical to the original PureFlex film product and offer the same well-characterised extractables profile and gas barrier properties. Because the fluid contact layer is the same in both films, current users of PureFlex film can incorporate PureFlex Plus technology with reduced validation requirements. Original PureFlex film will remain available, however, for customers uninterested in a film change.
"Biopharmaceutical manufacturers are increasingly incorporating single-use components into their processes to maximise efficiency and reduce costs," said Andrew Bulpin, Executive Vice President of Merck Millipore, Process Solutions. "The versatility of the single-use PureFlex film has allowed it to be used throughout the entire production process, limiting validation and implementation effort. The enhanced PureFlex Plus film adds further robustness to our proven film technology, helping to ensure process container integrity even in physically stressful applications."
Similar to its predecessor, PureFlex Plus film is a high purity, medical grade, coextruded film designed to provide strength, flexibility, low gas permeability, and an inert product contact layer. The fluid contact material is made of ultra low density polyethylene (ULDPE), the gas barrier layer is made of polyethylene vinyl alcohol copolymers (EVOH), and the first outer layer is made of ethylene vinyl acetate (EVA). All contact layers are free of animal-derived components and comply with the FDA regulation 21 CFR 177.1520. Using Merck Millipore's EZ fold technology, these flexible films allow for high-volume bag assemblies (> 500 L) to be filled in a bin without operator manipulation or the use of a hoist.
PureFlex films are used in the construction of Merck Millipore's Mobius assemblies and NovaSeptum sterile sampling products, which can be customised for any application. Business continuity plans have been established to ensure uninterrupted global supply of these films and products.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance